On Feb. 21, 2024, Change Healthcare experienced a cyber security incident. Any individuals impacted by this incident will receive a letter in the mail. Learn more about this from Change Healthcare, or reach out to the contact center at 1-866-262-5342.
Newsroom
Dear Provider,
Model of Care Training is Required
The Centers for Medicare & Medicaid Services (CMS) requires health plans to provide annual education and training on our Special Need’s Plans (SNP) Model of Care to providers who treat our SNP members. This applies to our Dual Eligible Special Needs Plan (D-SNP) members, who are eligible for both Medicare and Medicaid, and our Chronic Condition Special Needs Plan (C-SNP) members.
As stated in the Provider Manual, all providers who treat our SNP members regardless of network participation status must complete Model of Care (MOC) training annually by December 31st of each year.
The training is designed to help you better understand our approach to the delivery of care for SNP members.
How to access the training
The SNP MOC training is available for download and self-study at: https://www.wellcare.com/Providers/Model-of-Care-Training.
We appreciate the quality care you provide to our members and your support of our efforts to meet CMS regulations.
For additional information on how to work with our health plan to manage SNP members, please visit our Provider Resources page(s) at https://www.wellcare.com/Providers/Model-of-Care-Training. This site has links to the Provider Manual, Quick Reference Guides, Clinical Practice Guidelines, and more.
Step Therapy programs are developed by Wellcare's P&T Committee. They encourage the use of therapeutically equivalent, lower-cost medication alternatives (first-line therapy) before “stepping up” to alternatives that are usually less cost-effective.
Step Therapy programs are intended to be a safe and effective method of reducing the cost of treatment by ensuring that an adequate trial of a proven safe and cost-effective therapy is attempted before progressing to a more costly option. First-line drugs are recognized as safe, effective, and economically sound treatments.
The first-line drugs on Wellcare’s formulary have been evaluated through the use of clinical literature and are approved by Wellcare’s P&T Committee. Step therapy is failure of at least one different or less expensive drug prior to coverage of a drug on this list.
Drugs requiring step therapy effective January 01, 2024 are listed below. The prescriber, patient, or authorized representative may ask for an exception. Step therapy applies if the drug has not been used in the past 365 days.
Drug Name |
Abatacept (Orencia®) |
Ado-trastuzumab emtansine (Kadcyla®) |
Aflibercept (Eylea®) |
Atezolizumab (Tecentriq®) |
Axicabtagene ciloleucel (Yescarta®) |
Bevacizumab (Avastin®, Alymsys®, Mvasi®, Vegzelma™, Zirabev™) |
Brentuximab vedotin (Adcetris®) |
Brexucabtagene autoleucel (Tecartus™) |
Brolucizumab-dbll (Beovu®) |
Cemiplimab-rwlc (Libtayo®) |
Certolizumab (Cimzia®) |
Ciltacabtagene autoleucel (Carvykti™) |
Corticosteroid intravitreal implants: dexamethasone (Ozurdex®), fluocinolone acetonide (Iluvien®, Retisert®, Yutiq™) |
Corticotropin (H.P. Acthar®, Purified Cortrophin™ Gel) |
Daratumumab (Darzalex®), daratumumab/hyaluronidase-fihj (Darzalex Faspro™) |
Darbepoetin alfa (Aranesp®) |
Denosumab (Xgeva®) |
Durvalumab (Imfinzi®) |
Eflapegrastim-xnst (Rolvedon™) |
Elotuzumab (Empliciti®) |
Emapalumab-lzsg (Gamifant™) |
Epoetin alfa (Epogen®, Procrit®) |
Faricimab-svoa (Vabysmo™) |
Ferric carboxymaltose (Injectafer®) |
Ferric derisomaltose (Monoferric®) |
Ferric pyrophosphate (Triferic®, Triferic Avnu®) |
Ferumoxytol (Feraheme®) |
Filgrastim (Neupogen®, Zarxio®, Nivestym™, Granix®, Releuko®) |
Golimumab (Simponi®, Simponi Aria®) |
Hyaluronate derivatives: sodium hyaluronate (Euflexxa®, Gelsyn-3™, GenVisc®850, Hyalgan®, Supartz FX™, Synojoynt™, Triluron™, TriVisc™, VISCO-3™), hyaluronic acid (Durolane®), cross-linked hyaluronate (Gel-One®), hyaluronan (Hymovis®, Orthovisc®, Monovisc®), hylan polymers A and B (Synvisc®, Synvisc One®) |
Idecabtagene vicleucel (Abecma™) |
Immune globulins (Asceniv™, Bivigamâ, Cutaquigâ, Cuvitru™, Flebogammaâ DIF, GamaSTANâ, GamaSTANâ S/D, Gammagardâ liquid, Gammagardâ S/D, Gammaked™, Gammaplexâ, Gamunexâ-C, Hizentra®, HyQviaâ, Octagamâ, Panzygaâ, Privigenâ, Xembifyâ) |
IncobotulinumtoxinA (Xeomin®) |
Lisocabtagene maraleucel (Breyanzi®) |
Lurbinectedin (Zepzelca™) |
Luspatercept-aamt (Reblozyl®) |
Lutetium Lu 177 dotatate (Lutathera®) |
Nadofaragene firadenovec-vncg (Adstiladrin®) |
Natalizumab (Tysabri®) |
Nivolumab (Opdivo®) |
Pegfilgrastim (Neulasta®, Fulphila™, Fylnetra®, Nyvepria™, Stimufend®, Udenyca™, Ziextenzo™) |
Pembrolizumab (Keytruda®) |
Polatuzumab vedotin-piiq (Polivy™) |
Ramucirumab (Cyramza®) |
Ranibizumab (Lucentis®, Byooviz®, Cimerli™, Susvimo™) |
RimabotulinumtoxinB (Myobloc®) |
Rituximab (Rituxan®, Riabni™, Ruxience™, Truxima®), rituximab/hyaluronidase (Rituxan Hycela™) |
Romiplostim (Nplate®) |
Romosuzumab-aqqg (Evenity™) |
Sargramostim (Leukine®) |
Sipuleucel-T (Provenge®) |
Teclistamab-cqyv (Tecvayli®) |
Teprotumumab-trbw (Tepezza™) |
Tisagenlecleucel (Kymriah®) |
Tocilizumab (Actemra®) |
Trastuzumab (Herceptin®, Ontruzant®, Herzuma®, Ogivri™, Trazimera™, Kanjinti™), trastuzumab/hyaluronidase (Herceptin Hylecta™) |
Triamcinolone ER injection (Zilretta®) |
Vedolizumab (Entyvio®) |
Verteporfin (Visudyne®) |
Medicare Prior Authorization
List effective 10/1/2023
Wellcare Oklahoma requires prior authorization (PA) as a condition of payment for many services. This Notice contains information regarding such prior authorization requirements and is applicable to all Medicare products offered by Wellcare.
Wellcare is committed to delivering cost effective quality care to our members. This effort requires us to ensure that our members receive only treatment that is medically necessary according to current standards of practice. Prior authorization is a process initiated by the physician in which we verify the medical necessity of a treatment in advance using independent objective medical criteria and/or in network utilization, where applicable.
It is the ordering/prescribing provider’s responsibility to determine which specific codes require prior authorization.
Please verify eligibility and benefits prior to rendering services for all members. Payment, regardless of authorization, is contingent on the member’s eligibility at the time service is rendered. NON-PAR PROVIDERS & FACILITIES REQUIRE AUTHORIZATION FOR ALL HMO SERVICES EXCEPT WHERE INDICATED.
For complete CPT/HCPCS code listing, please see Online Prior Authorization Tool on our website at WellcareOK.com.
Effective October 1st, 2023, the following are changes to prior authorization requirements:
Service Category |
PA Rule | Services | Procedure Codes |
Audiology | No PA Required | Pure tone audiometry | 0208T, 0209T |
Behavioral Health | No PA Required | Alcohol and/or drug services | H0010, H0011, H0012, H0014, H0016, H0018 |
Assertive community treatment, face-to-face | H0039 | ||
BH and Community Support Services | H2001, H2012, H2016, H2018, H2020, H2022, H2030, H2034, H2036 | ||
Crisis intervention mental health services, per hour | S9484, S9485 | ||
Adaptive behavior treatment | 97157 | ||
Breast Reconstruction | No PA Required | Repair and/or reconstruction | 19357, 19367, 19368, S2068 |
Cardiovascular | PA Required | Coronary intravascular lithotripsy (IVL) procedure | 0715T |
Pacemaker/cardioverter-defibrillator devices and procedures | C1899, G0448 | ||
No PA Required | Device interrogation and analysis | 0418T | |
Transcatheter valve and cardiac procedures | 0483T, 0569T, 0644T | ||
DME & Supplies | PA Required | Hospital bed and mattress | E0302, E0372, E0462 |
Respiratory systems and supplies | E0440, E0467 | ||
Patient lifts | E0639 | ||
Pneumatic & non-pneumatic compressor devices | E0657, E0665, E0666, E0669, E0670, E0672, K1024, K1033 | ||
Ultraviolet light therapy | E0691, E0694 | ||
Wheelchairs, power operated vehicles, and accessories | E0983, E0985, E0988, E1004, E1036, E1070, E1084, E1087, E1170, E1222, E1223, E1228, E1239, E1270, E1280, E1296, E1298, E2328, E2341, E2343, E2358, E2362, E2364, E2368, E2369, E2610, E2614, E2625, E2631, E2632, E2633, K0008, K0009, K0011, K0012, K0014, K0015, K0046, K0065, K0098, K0669, K0802, K0807, K0812, K0814, K0815, K0829, K0850, K0851, K0852, K0853, K0860, K0864, K0877, K0878, K0884, K0891, K0898, K0899 | ||
Nerve stimulating device | K1018 | ||
Speech generating device/accessory | E2502 | ||
Automatic external defibrillator | K0606 | ||
No PA Required | Compression burn garment | A6507 | |
Hospital bed, mattress, and supplies | E0181, E0182, E0189, E0305, E0310, E0316, E0328 | ||
Electronic bowel irrigation system | E0350 | ||
Delivery/installation charges for hemodialysis equipment | E1600 | ||
Heat, cold, and light therapies | E0202, E0217, E0221 | ||
Respiratory systems, devices and supplies | A7047, E0435, E0455, E0472, E0500 | ||
Breast pump, hospital grade, electric | E0604 | ||
Monitoring equipment | E0619, E0620 | ||
Functional electrical stimulator | E0770 | ||
Traction and other orthopedic devices | E0856, E0944 | ||
Wheelchairs and accessories | E0968, E0969, E0980, E0994, E1014, E1029, E1092, E1093, E1160, E1229, E1232, E1233, E1234, E1235, E1236, E1237, E1238, E2291, E2292, E2293, E2294, E2301, E2324, E2381, E2382, E2384, E2385, E2386, E2387, E2388, E2389, E2390, E2391, E2392, E2394, E2395, E2396, K0017, K0018, K0020, K0053, K0105, K0195 | ||
Blood glucose monitor | E2100, E2102 | ||
Evaluation & Management | No PA Required | Nursing facility care plan oversight | 99306, 99379 |
Medication therapy management | 99605, 99606, 99607 | ||
General Surgery | PA Required | Repair procedures on the nose | 30410, 30420, 30430, 30520 |
Procedures on the stomach | 43881 | ||
Procedures on the penis | 54400, 54401, 54405 | ||
Phrenic nerve stimulation system procedure | 0435T | ||
Benign thyroid nodule ablation | 0673T | ||
No PA Required, unless managed by a vendor in select markets | Removal of abdominal mesh | 11008 | |
Removal of skin tags procedures | 11200, 11201 | ||
Skin color correction | 11920, 11921, 11922 | ||
Tissue expanders | 11960, 11970, 11971 | ||
Skin therapies | 15786, 15787, 17360 | ||
Trigger point injections | 20552, 20553 | ||
Cranial/facial repairs | 21175, 21181, 21183, 21193, 21230, 21256, 21280 | ||
Repair procedures on the nose | 30460, 30462, 30560, 30630 | ||
Transplant related procedures | 32855, 32856, 33933, 33940, 33944, 38206, 38207, 38208, 38209, 38214, 38215, 38230, 47143, 48551, 48552, 50300, 50320, 50323, 50325, 50327, 50328, 50329, 50370 | ||
Repair procedures on the urethra | 52010, 52301, 52343, 53420 | ||
Excision procedures on the endocrine system | 60212, 60505 | ||
Procedures on the spine/spinal cord | 22527, 62367, 62368, 62370 | ||
Procedures on the cardiovascular system | 33952, 36836, 36837 | ||
Procedures on the spleen | 38129 | ||
Procedures on the diaphragm | 39599 | ||
Procedures on the digestive system | 43283, 43772, 43774, 44145, 64595 | ||
Neurostimulator procedures on the peripheral nerves | 64585 | ||
GI Services | No PA Required | Transnasal EGD | 0652T, 0653T |
Gynecology | No PA Required | Excision/repair of the vulva, vagina | 56625, 57291, 57292 |
Hysterectomy procedures | 58150, 58152, 58180, 58200, 58210, 58240, 58260, 58262, 58263, 58270, 58275, 58280, 58290, 58291, 58292, 58541, 58542, 58543, 58544, 58548, 58550, 58552, 58553, 58554, 58570, 58571, 58572, 58573, 58575, 58951, 58953, 58954, 58956 | ||
Myomectomy, ovarian/tubal resection | 58545, 58546, 58661, 58720, 58940, 58952 | ||
Home Care | No PA Required | Home care services | S5145, S5150 |
Contracted home health | T1022 | ||
Injection Procedures | PA Required | Percutaneous lumbar intravertebral disc injection | 0627T, 0628T |
No PA Required | Injection of the spine/spinal cord | 62280, 62290, 62291, 62324, 62325, 62326, 62327 | |
Maternity | No PA Required | Maternity care | 59866, 59897 |
Medicine Services & Procedures | No PA Required, unless managed by a vendor in select markets | Instillation, bupivacaine and meloxicam, 1 mg/0.03 mg | C9088 |
Immune globulins, serum or recombinant product | 90283 | ||
Special otorhinolaryngologic procedures | 92512, 92516, 92520, 92546, 92597, 92607, 92608, 92609, 92610, 92700 | ||
Neurology testing | 95700, 95803 | ||
Chiropractic treatment | 98940, 98941, 98942 | ||
Education and training for patient self-management | 98960 | ||
Nutrition | No PA Required | Medical nutrition therapy | 97804 |
Enteral formulas and additives | B4157, B4158, B4159, B4162, B9006 | ||
Medical foods for inborn errors of metabolism | S9435 | ||
Orthopedics | PA Required | Insertion sinus tarsi implant | 0335T |
Sacroiliac joint arthrodesis procedure | 0775T | ||
Ophthalmology | No PA Required | Open–eye eyelid treatment device | 0563T |
Other procedures on the cornea | 65765 | ||
Orthotics and Prosthetics | PA Required | Spinal orthotics | L0458, L0468, L0480, L0484, L0632, L0638, L0639, L0640, L0651, L1200, L1300 |
Lower extremity orthotics | E1830, L1690, L1840, L1904, L2000, L2005, L2030, L2034, L2038, L2525, L2627, L2628 | ||
Upper extremity orthotics | E1802, E1818, E1840 | ||
Lower extremity prosthetics | K1014, L5010, L5060, L5200, L5505, L5510, L5520, L5535, L5560, L5570, L5600, L5610, L5614, L5628, L5630, L5638, L5639, L5640, L5661, L5682, L5702, L5795, L5818, L5824, L5826, L5830, L5858, L5859, L5930, L5966, L5969, L5982, L5990 | ||
Upper extremity prosthetics | L6000, L6010, L6020, L6200, L6250, L6320, L6400, L6623, L6628, L6638, L6646, L6647, L6692, L6697, L6704, L6711, L6712, L6883, L6885, L6895, L6900, L6905, L6910, L6920, L6925, L6940, L6945, L6950, L6965, L7405 | ||
Cochlear device | L8614 | ||
Orbital prosthetics | L8042 | ||
Unlisted prosthetics | L8499 | ||
No PA Required | Penile devices | C2622, L7900 | |
Spinal orthotics | L0700, L0710 | ||
Upper extremity orthotics | L0170, L0190, L3671, L3674, L3962 | ||
Lower extremity orthotics | L0469, L0470, L1000, L1270, L1640, L1730, L1847, L1860, L2126, L2136, L2570, L2580 | ||
Cochlear implant device components | L8627, L8628, L8629 | ||
Pretibial shell | L4130 | ||
Prosthetic fitting, immediate post-surgical | L5400, L5420, L5430 | ||
Nasal and facial prosthesis | L8040, L8046, V2629 | ||
Finger prosthetics | L8659 | ||
Pain Management | PA Required | Percutaneous cranial nerves stimulation | 0720T |
Injection of anesthetic agent (nerve block) | 64450, 64451, 64494 | ||
Destruction by neurolytic agent | 64624 | ||
Pathology and Laboratory | PA Required | Genetic analysis | 81265, 81266 |
No PA Required | Multianalyte assays | 0014M | |
Proprietary laboratory analyses | 0035U, 0040U, 0219U, 0353U | ||
Therapeutic drug assays | 80220 | ||
Genetic analysis | 81224, 81239, 81262, 81316, 81341 | ||
Multianalyte assays w/algorithmic analyses | 81508, 81511, 81512, 81513, 81514, 81528 | ||
Chemistry procedures | 82077, 82105, 82397, 82657, 82677, 84163, 84702, 84704, 84999 | ||
Qualitative or semiquantitative immunoassays | 86152, 86336 | ||
Postmortem examination | 88025 | ||
Flow cytometry, cytogenetic studies | 88182, 88230, 88233, 88235, 88237, 88263, 88269, 88291 | ||
Surgical pathology | 88364, 88365, 88366, 88367, 88368, 88369, 88373, 88374, 88377, 88381 | ||
Reproductive medicine | 89310, 89320, 89321 | ||
Pharmacy | No PA Required | Pharmacy dispensing fee for inhalation drug(s) | Q0513, Q0514 |
Pharmacy compounding and dispensing services | S9430 | ||
Professional Services | No PA Required | Molecular pathology procedure; physician interpretation and report | G0452 |
Hospital observation service and admission | G0378, G0379 | ||
Radiology Services | No PA Required – except when managed by vendor in select markets | PET imaging, any site, NOS | G0235 |
ERCP with endomicroscopy | 0397T | ||
Quantitative ultrasound tissue characterization | 0690T | ||
Fetal MRI | 74713 | ||
Endocrine system | 78012, 78013, 78014, 78018, 78070, 78071, 78072 | ||
Bone marrow imaging | 78102 | ||
Gastrointestinal system | 78201, 78202, 78215, 78216, 78226, 78227 | ||
Cardiovascular system | 75565, 78434 | ||
Radiopharmaceutical localization of tumor | 78800, 78804 | ||
Radiopharmaceuticals | PA Required | Lutetium lu 177 vipivotide tetraxetan, therapeutic | A9607 |
No PA Required | Radiopharmaceutical, diagnostic, not otherwise classified | A4641 | |
Fluorodeoxyglucose F-18 FDG, diagnostic, per study dose | A9552 | ||
Rubidium Rb-82, diagnostic, per study dose | A9555 | ||
Skin Substitute | PA Required | Skin substitute products | Q4199 |
No PA Required | Autograft suspension | C1832 | |
Specialty Medications | PA Required | Injectable Medication | J1950, J2182, J2786, J9214, J9044 |
Intravitreal implant | J7313 | ||
Hyaluronic injections | J7322, J7328 | ||
No PA Required | Inhalation medications | J7605, J7606, J7626 | |
Injectables | J0121, J0572, J0573, J0574, J1750, J1756, J2212, J2440, J1453, J3489, S0039, S0080 | ||
Other medication | S0091, S0157 | ||
Therapy Services | No PA Required, unless managed by a vendor in select markets | Physical medicine and rehab evaluations | 97164, 97168, 97169, 97170, 97172, 97750 |
Occupational therapy services, qualified occupational therapist | G0129 | ||
Speech, language, dysphagia screenings | V5362, V5363, V5364 | ||
Electrical stimulation, (unattended) | G0281, G0282 | ||
Wound Care | PA Required | Active wound care management – PA required after 12 combined wound care visits per calendar year | 97597, 97598, 97602 |
Electrical stimulation and cutaneous wound healing | 0512T | ||
Matrix for wound management | A2001, A2002, A2004, A2005, A2007, A2015 |
Who is Express Scripts?
Express Scripts is a pharmacy benefit management (PBM) company serving more than 100 million Americans. Express Scripts Pharmacy delivers specialized care that puts patients first through a smarter approach to pharmacy services.
What is the rationale for changing PBM vendors?
Express Scripts as our PBM will bring increased levels of transparency and value, positioning us to provide the highest level of quality at the lowest possible cost to our members.
What PBM services will Express Scripts be providing?
Express Scripts will be the PBM of record providing pharmacy claims adjudication, pharmacy network administration and rebate administration on behalf of our health plan.
How will this PBM transition impact our members?
There will be no immediate change in service for our members, although they will receive new ID cards. We will continue to provide the same member-focused care and support as we do today.
Our highest priority continues to be serving all our members, and we remain committed to providing affordable quality healthcare services. Our team is working closely with both CVS and Express Scripts to ensure a seamless migration.
Is Amazon part of the Express Scripts Network?
Yes, Amazon is part of the Express Scripts network.
Can members still use CVS Caremark for their mail orders?
No, CVS Caremark Mail Service Pharmacy will be out of network, effective January 1, 2024. If members wish to continue using mail order in 2024, they must switch to Express Scripts Pharmacy.
Do members have a choice besides Express Scripts for mail order services?
Members have a choice to use other pharmacies that offer home delivery but Epress Scripts Pharmacy is the preferred mail order pharmacy for our health plan.
Are we communicating this mail order change to members?
Yes. Impacted Medicaid members will receive a Mail Order Change notification letter.
How will members get started with mail order at Express Scripts?
For existing mail order users:
- Most open prescription refills will be automatically transferred to Express Scripts
- Refills for controlled drugs, such as Alprazolam, Clonazepam, Pregabalin, Tramadol, Zolpidem, etc., will not automatically transfer to Express Scripts Pharmacy; members must request a new prescription from their provider
For new mail order prescriptions on or after January 1, 2024, members may do one of the following:
- Ask their provider to electronically submit or fax a new prescription to Express Scripts Pharmacy, as listed on their medical ID cards
- Visit express-scripts.com/rx to register or sign in, then follow the guided steps to request a prescription
- Call Express Scripts Pharmacy, who will contact their provider for a new prescription to be filled via mail order
- Mail a Home Delivery Order Form (available at express-scripts.com/rx) directly to Express Scripts Pharmacy
Does Express Scripts offer a mail order app?
Yes, members will be able to download the Express Scripts Pharmacy app, available on the App Store and Google Play. Members with a mail order benefit can order medications, track delivery and more.
PRO_ 2435207_E_Internal Approved 10102023
We are pleased to announce that, effective January 1, 2024, Express Scripts® will begin processing pharmacy claims for our plan members.
Express Scripts is a pharmacy benefit management (PBM) company serving more than 100 million Americans. Express Scripts Pharmacy delivers specialized care that puts patients first through a smarter approach to pharmacy services.
Members have been notified in advance and will receive a new ID card with updated pharmacy information, so that they are prepared to begin having their prescriptions filled at participating network pharmacies when this change occurs.
Providers can direct members to call the Member Services phone number listed on their ID card should they have questions about this change.
Please contact your Provider Relations Representative with any additional questions.
Thank you for the care you provide to our members.
PRO_2433922E_State/Internal Approved 09272023
Earlier this year, the Biden Administration announced that the federal Public Health Emergency (PHE) related to the COVID-19 pandemic will end on May 11, 2023.
During the PHE, we followed guidance from the Centers for Medicaid & Medicare Services (CMS) and instituted temporary waivers for select services. This action ensured that critical care could be quickly delivered to our members during a time of heightened need. Beginning May 12, 2023, these temporary waivers will expire, and our members’ Medicare plan benefits will be reinstated for the following services:
Service | Member Liability | Prior Auth Needed? |
COVID-19 Testing and Screening (Administered by Provider) | Per member plan benefits | No |
COVID-19 Vaccinations | $0 member cost-share for vaccine administration* | No |
COVID-19 Monoclonal Antibody Treatments | $0 member cost-share for treatment administration* | Prior authorization only required for CPT code Q0221 |
*Vaccine ingredient cost is still covered directly by Medicare FFS.
Alongside these waivers, the Coronavirus Aid, Relief, and Economic Security (CARES) Act provided for a 20% increase to the inpatient prospective payment system (IPPS) Diagnosis Related Group (DRG) rate for COVID-19 patients for the duration of the public health emergency. This increase applied to claims that included the applicable COVID-19 ICD-10-CM diagnosis code and met the date of service requirement. When the PHE ends on May 11, 2023, these add-on payments will no longer be included for discharge dates of service as of May 12, 2023 and thereafter.
Wellcare is committed to providing a smooth transition for both our members and providers as we resume business as usual. While we will continue to communicate any updates to our business practices directly to our provider partners, we always highly recommend that providers verify member eligibility, benefits, and prior authorization requirements before rendering services.
Material ID: PRO_2081305E Internal Approved 05112023
List effective 7/1/2023
Wellcare Oklahoma requires prior authorization (PA) as a condition of payment for many services. This Notice contains information regarding such prior authorization requirements and is applicable to all Medicare products offered by Wellcare Oklahoma.
Wellcare Oklahoma is committed to delivering cost effective quality care to our members. This effort requires us to ensure that our members receive only treatment that is medically necessary according to current standards of practice. Prior authorization is a process initiated by the physician in which we verify the medical necessity of a treatment in advance using independent objective medical criteria and/or in network utilization, where applicable.
It is the ordering/prescribing provider’s responsibility to determine which specific codes require prior authorization.
Please verify eligibility and benefits prior to rendering services for all members. Payment, regardless of authorization, is contingent on the member’s eligibility at the time service is rendered. NON-PAR PROVIDERS & FACILITIES REQUIRE AUTHORIZATION FOR ALL HMO SERVICES EXCEPT WHERE INDICATED. For complete CPT/HCPCS code listing, please see Online Prior Authorization Tool on our website at https://www.oklahomacompletehealth.com/providers/preauth-check/medicare-pre-auth.html
List effective 1/1/2022
Wellcare requires prior authorization (PA) as a condition of payment for many services. This Notice contains information regarding such prior authorization requirements and is applicable to all Medicare products offered by Wellcare.
Wellcare is committed to delivering cost effective quality care to our members. This effort requires us to ensure that our members receive only treatment that is medically necessary according to current standards of practice. Prior authorization is a process initiated by the physician in which we verify the medical necessity of a treatment in advance using independent objective medical criteria and/or in network utilization, where applicable.
It is the ordering/prescribing provider’s responsibility to determine which specific codes require prior authorization.
Please verify eligibility and benefits prior to rendering services for all members. Payment, regardless of authorization, is contingent on the member’s eligibility at the time service is rendered. NON-PAR PROVIDERS & FACILITIES REQUIRE AUTHORIZATION FOR ALL HMO SERVICES EXCEPT WHERE INDICATED.
For complete CPT/HCPCS code listing, please see Online Prior Authorization Tool on our website at www.oklahomacompletehealth.com/providers/preauth-check/medicare-pre-auth
Effective January 1st, 2023, the following are changes to prior authorization requirements:
In an effort to continue promotion of quality improvement for services provided to our members, Ambetter and WellCare of Oklahoma are pleased to announce a partnership with National Imaging Associates, Inc (NIA).
Ambetter, WellCare and NIA encourage our providers to attend an upcoming provider education webinar on the various programs administered by NIA. There are several one-hour webinar sessions that will take place on the following dates.
To register for one these informative webinars, please click the Provider Training link on the Oklahoma Complete Health website.* www.oklahomacompletehealth.com/providers/resources/provider-training.html
*It is recommended but not mandatory that you RSVP at least one week prior to the training that you plan to attend by registering for one of the education sessions above.
You will receive a registration confirmation email from NIA for the Webinar session you selected. It is recommended that computer access is utilized if possible, to view educational documents during the webinar. To access the webinar by computer, please click on the link for the session you would like to attend or type the URL address into your browser. Please see call in instructions below if you do not have computer access.
NIA, Ambetter and Wellcare of Oklahoma look forward to working with you to ensure that your patients, our members receive services delivered in a quality, clinically appropriate fashion.
If you have questions about this bulletin or other provider resources, please contact the Oklahoma Complete Health Provider Support team at:
OklahomaCompleteHealth_PR@OCH.com
Or call Provider Services at:
- Ambetter of Oklahoma (Marketplace): 1-833-492-0679 (TTY: 711)
- Wellcare Oklahoma (Medicare Advantage): 1-833-853-0865 (TTY: 711)
Beginning on September 1, 2022, Wellcare of Oklahoma will be collaborating with Optum, to ensure consistency in claims review and reimbursement practices with our hospital partners by reviewing all facility claims that exceed outlier thresholds.
Effective September 1, 2022, will require submission of itemized bills with high dollar facility claims. You must submit an itemized detail listing each supply and service provided to the patient and match the billed charge amount for the underlying claim for submission of all facility outlier claims.
Itemized Bill Requirements:
- The itemized bill must list each supply and services provided to the member, match the dollar amount and date of service of the request.
- The request will apply to claims submitted with other insurance, changes in coverage, lapse in coverage, or if the member’s coverage termed during the length of stay.
- Interim billing will not require an itemized bill, however it will be requested once the final bill has been submitted.
How will Company communicate its findings?
If Optum identifies any billing issues during its review, it will send you detailed findings regarding these issues and provide you with a direct contact with whom you can discuss and resolve any issues you may have with its findings. You can also exercise your right to formally appeal Optum’s finding.
Questions:
If you have questions about this communication, please contact Provider Relations at pr_wellcare_ok@oklahomacompletehealth.com.
Thank you for your continued partnership with Wellcare. As you know, we continually review and update our payment and utilization policies to ensure that they are designed to comply with industry standards while delivering the best patient experience to our members.
Wellcare is issuing a new policy effective *4/1/2022*.
Policy Number: CC.PP.071
Policy Name: Evaluation and Management Services Billed with Treatment Rooms
Policy Description: Disallows E&M services in treatment rooms as this does not represent a treatment type of service.
Lines of Business: Medicare
For detailed information about this policy, please refer to our Clinical & Payment Policies [link: https://www.wellcareok.com/for-providers/clinical-payment-policies.html]. And for questions about this or any of our payment policies, please don’t hesitate to reach out to our Provider Services team at 1-833-853-0865.
Dear Valued Provider,
To reduce administrative burden on our provider partners, Wellcare is making the following changes to both our peer-to-peer review request requirements and elective medical inpatient authorization process. This will impact peer-to-peer and elective medical inpatient authorization requests received on or after the elective dates outlined below.
Peer-to-Peer Review Requests Change Effective 10/1/2022
In order to ensure accurate delivery and reimbursement for medically necessary services to our members, Wellcare is updating our requirements for peer-to-peer review effective 10/1/2022 to the following:
- Peer-to-peer review requests will be allowed up to two (2) business days after Integrated Denial Notice or day of discharge, whichever is later.
- Peer-to-peer outreach will be completed within 2 business days of peer-to-peer review request.
- If provider is not reached, a voice mail will be left (if possible) giving provider one business day to respond.
- If the provider does not respond within the stipulated timeframe, Wellcare will be unable to proceed with peer-to-peer request.
No changes are being made to existing peer-to-peer timeframes or processes for pre-service requests.
Elective Medical Inpatient Authorization Process Change Effective 11/1/2022
To provide increased flexibility and better align with industry best practices, we are making the following changes to our elective medial inpatient authorization process effective 11/1/2022:
- The prior authorization span for elective inpatient admissions will be increased to 60 (sixty) days for dates of service on or after 11/1/2022.
- If the planned admission date exceeds the authorized date span of 60 days, a new authorization span is required.
- Elective Inpatient Prior Authorization numbers will now start with the prefix of OP instead of IP.
- Notification of admission is required within one (1) business day of admit. At the time of admission notification, a new authorization number for the admission will be provided with the IP prefix. Failure to provide timely notification may result in a denial of payment.
As a reminder, all planned/elective admissions to the inpatient setting require prior authorization. Prior authorization should be requested at least five (5) days before the scheduled service delivery date or as soon as need for service is identified. If prior authorization is not on file at the time of elective admission, the service is considered retrospective, and provider should follow the appropriate retrospective request process as communicated in the provider notice. Emergent admissions do not require prior authorization.
Thank you for continuing to provide our Medicare members with high quality and compassionate care. If you have questions about any of this information, please contact Provider Services.
Sincerely,
Wellcare
As a valued provider partner, we’d like to remind you to review your National Provider Identifier (NPI) data in National Plan & Provider Enumeration System (NPPES) as soon as possible to ensure that accurate provider data is displayed. As you may know, providers are legally required to keep their NPPES data current. Centers for Medicare & Medicaid Services (CMS) is also encouraging Medicare Advantage Organizations to use NPPES as a resource for our online provider directories. By using NPPES, we can decrease the frequency by which we contact you for updated directory information and provide more reliable information to Medicare beneficiaries.
If the NPPES database is kept up to date by providers, our organization can rely on it as a primary data resource for our provider directories, instead of calling your office for this information. With updated information, we can download the NPPES database and compare the provider data to the information in our existing provider directory to verify its accuracy.
When reviewing your provider data in NPPES, please update any inaccurate information in modifiable fields including provider name, mailing address, telephone and fax numbers, and specialty, to name a few. You should also make sure to include all addresses where you practice and actively see patients and where a patient can call and make an appointment. Do not include addresses where you could see a patient, but do not actively practice. Please remove any practice locations that are no longer in use. Once you update your information, you will need to confirm it is accurate by certifying it in NPPES. Remember, NPPES has no bearing on billing Medicare Fee-For-Service.
If you have any questions pertaining to NPPES, you may reference NPPES help at https://nppes.cms.hhs.gov/webhelp/nppeshelp/HOME%20PAGE-SIGN%20IN%20PAGE.html.
Please direct any general questions about this notice to your provider relations representative.